ConductScience.org, home

Paper17519122

Compliance and fixed-dose combination therapy.

Bangalore S and 3 others. Curr Hypertens Rep, 2007. Cited by 46 papers, by iCite.

Cite this record

ConductScience Library. Compliance and fixed-dose combination therapy. Papers, record 17519122. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17519122

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Compliance and fixed-dose combination therapy.
PubMed
Journal
Curr Hypertens Rep
PubMed
Year
2007
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
46
iCite
Relative citation ratio, by iCite
1.35
iCite
Revised in PubMed
2022-07-16
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bangalore SSripal
2Shahane AAnupama
3Parkar SSanobar
4Messerli FHFranz H

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antihypertensive AgentsMajor topic
HypertensionMajor topic
Patient ComplianceMajor topic
Blood Pressure
Cost-Benefit Analysis
Dose-Response Relationship, Drug
Drug Combinations
Humans
Risk Factors
Treatment Refusal

Source PubMed

Download CSV of topics

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116870079Overcoming barriers to effective blood pressure control in patients with hypertension.Curr Med Res Opin2006https://conductscience.org/library/papers/16870079PubMed
211465916Achieving blood pressure targets in the management of hypertension.Blood Press Suppl2001https://conductscience.org/library/papers/11465916PubMed
315076203Foot volume increase on nifedipine is not prevented by pretreatment with diuretics.J Hypertens2004https://conductscience.org/library/papers/15076203PubMed
415652604Global burden of hypertension: analysis of worldwide data.Lancet2005https://conductscience.org/library/papers/15652604PubMed
516494640Initiation of hypertension treatment with a fixed-dose combination or its monocomponents -- does it really matter?Int J Clin Pract2006https://conductscience.org/library/papers/16494640PubMed
612441226Pedal edema--not all dihydropyridine calcium antagonists are created equal.Am J Hypertens2002https://conductscience.org/library/papers/12441226PubMed
712556541Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.N Engl J Med2003https://conductscience.org/library/papers/12556541PubMed
89518949Managing the patient with hard-to-control hypertension.Am Fam Physician1998https://conductscience.org/library/papers/9518949PubMed
912748199The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.JAMA2003https://conductscience.org/library/papers/12748199PubMed
1012829553A strategy to reduce cardiovascular disease by more than 80%.BMJ2003https://conductscience.org/library/papers/12829553PubMed
1111952029Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy.Clin Ther2002https://conductscience.org/library/papers/11952029PubMed
121728930
Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group.
Arch Intern Med1992https://conductscience.org/library/papers/1728930PubMed
1311713851The multifactorial nature of hypertension: the greatest challenge for its treatment?J Hypertens Suppl2001https://conductscience.org/library/papers/11713851PubMed
1412418941Prevalence, expenditures, and complications of multiple chronic conditions in the elderly.Arch Intern Med2002https://conductscience.org/library/papers/12418941PubMed
1515631534Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide.Am J Cardiovasc Drugs2005https://conductscience.org/library/papers/15631534PubMed
1615908846Impact of medication adherence on hospitalization risk and healthcare cost.Med Care2005https://conductscience.org/library/papers/15908846PubMed
179635947Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.Lancet1998https://conductscience.org/library/papers/9635947PubMed
1816470077Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002.J Clin Hypertens (Greenwich)2006https://conductscience.org/library/papers/16470077PubMed
1911827559Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats.Drugs2002https://conductscience.org/library/papers/11827559PubMed
2014564133Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance.J Clin Hypertens (Greenwich)2003https://conductscience.org/library/papers/14564133PubMed

See all 39 referencesDownload CSV of references

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.

PMIDTitleJournalYearIn PapersSource
41504880Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41504880PubMed
38319595
Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial.
J Clin Hypertens (Greenwich)2024https://conductscience.org/library/papers/38319595PubMed
36843692Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials.Cureus2023https://conductscience.org/library/papers/36843692PubMed
345754483D Printing of Pharmaceutical Application: Drug Screening and Drug Delivery.Pharmaceutics2021https://conductscience.org/library/papers/34575448PubMed
34504874Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe.Front Cardiovasc Med2021https://conductscience.org/library/papers/34504874PubMed
32098393Does the Polypill Improve Patient Adherence Compared to Its Individual Formulations? A Systematic Review.Pharmaceutics2020https://conductscience.org/library/papers/32098393PubMed
30582181Development of an entirely remote, non-physician led hypertension management program.Clin Cardiol2019https://conductscience.org/library/papers/30582181PubMed
30568434Factors influencing adherence to treatment in older adults with hypertension.Clin Interv Aging2018https://conductscience.org/library/papers/30568434PubMed
29081008Hypertension in African Americans.Curr Cardiol Rep2017https://conductscience.org/library/papers/29081008PubMed
28608025Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.High Blood Press Cardiovasc Prev2017https://conductscience.org/library/papers/28608025PubMed
28166827The polypill approach - An innovative strategy to improve cardiovascular health in Europe.BMC Pharmacol Toxicol2017https://conductscience.org/library/papers/28166827PubMed
27891352Herbal Fixed Dose Combinations in Nepal: Growing Concerns in a Developing Country.J Clin Diagn Res2016https://conductscience.org/library/papers/27891352PubMed
27536448Evaluation of effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide single-pill combination therapy in hypertensive patients: an observational study.J Drug Assess2014https://conductscience.org/library/papers/27536448PubMed
25525383Antihypertensive combination therapy in primary care offices: results of a cross-sectional survey in Switzerland.Int J Gen Med2014https://conductscience.org/library/papers/25525383PubMed
24985411Efficacy and safety of valsartan/amlodipine single-pill combination in 11,422 Chinese patients with hypertension: an observational study.Adv Ther2014https://conductscience.org/library/papers/24985411PubMed
24136760Factors that interfere the medication compliance in hypertensive patients.Einstein (Sao Paulo)2013https://conductscience.org/library/papers/24136760PubMed
23630412Phentermine and topiramate for the management of obesity: a review.Drug Des Devel Ther2013https://conductscience.org/library/papers/23630412PubMed
21949631Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination.Integr Blood Press Control2010https://conductscience.org/library/papers/21949631PubMed
19499963
Effectiveness and tolerability of fixed-dose combination enalapril plus nitrendipine in hypertensive patients: results of the 3-month observational, post-marketing, multicentre, prospective CENIT study.
Clin Drug Investig2009https://conductscience.org/library/papers/19499963PubMed
18691228A novel programme to evaluate and communicate 10-year risk of CHD reduces predicted risk and improves patients' modifiable risk factor profile.Int J Clin Pract2008https://conductscience.org/library/papers/18691228PubMed

See all 21 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17519122

GET https://conductscience.org/api/papers/v1/17519122/references?page=2